This text is a result of machine translation.
Autonomous Driving Goes Abroad: Why Singapore Is the First Stop in Southeast Asia
When Chinese autonomous driving technology companies set their sights on Southeast Asia, Singapore almost invariably becomes the “first coordinate” on every roadmap. In 2025, Singapore has offered not only certainty for those planning to enter, but also a stage for those already here.
Oct 23, 2025 08:03 PM
Electric Vehicles to Account for Two-thirds of Global Vehicle Sales by 2030
Week's Go Global Information Gap (11/23–11/29): The US launched the AI "Genesis Project"
Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.
Nov 28, 2025 06:10 PM
China and U.S. Agree to Pause Certain Tariffs and Export Restrictions
On October 30, China’s Ministry of Commerce (商务部) officially released the outcomes of the China–U.S. trade consultations held in Kuala Lumpur. Building on the consensus reached during the China–U.S. presidential meeting in Busan, the two countries’ economic and trade teams achieved substantive breakthroughs on key issues such as tariffs and export controls, providing a strong boost of confidence to the global economy.
Oct 30, 2025 05:35 PM
We-Linking Raised Over CNY 10 Mn in Angel Round
Intraoperative Neurophysiological Monitoring Equipment Developer NeuroFlag Closed An Angel Round
Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A
QCraft Debuts at Japan Mobility Show, Starts L4 Robobus Commercial Deployment in Japan
QCraft debuted at the 2025 Japan Mobility Show (49th Tokyo Motor Show), presenting its first mature L4 autonomous products for Japan — the Robobus and its full-stack autonomous driving solution — signaling the start of its commercial rollout in the country.
Oct 29, 2025 05:29 PM
CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM
There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?
Apr 27, 2022 09:45 PM
China biopharmaceutical: the fifth indication of anti-tumor drug "arotinib hydrochloride capsule" has been approved
Jin Litai: the prices of various types of cathodic electrophoretic paint products rise by 10% - 20%